NASDAQ · SEERHealthcareLab Analytical Instruments

Seer financials

$2.15+5.91%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$16.6M$14.2M$16.7M$15.5M$6.6M$656.0K
Gross profit$8.5M$7.1M$8.5M$7.1M$3.4M$656.0K
Gross margin51.1%49.8%51.1%45.8%51.6%100.0%
Operating income-$78.0M-$100.1M-$103.5M-$97.2M-$71.5M-$33.6M
Net income-$73.6M-$86.6M-$86.3M-$93.0M-$71.2M-$32.8M
Net margin−444.0%−611.1%−517.8%−600.1%−1075.5%−4996.2%
Diluted EPS$-1.28$-1.39$-1.35$-1.49$-1.17$-2.48
EBITDA-$71.9M-$93.9M-$97.9M-$93.3M-$68.9M-$32.0M
Operating cash flow-$44.4M-$46.1M-$59.1M-$60.8M-$46.3M-$20.8M
Free cash flow-$46.2M-$49.7M-$66.4M-$71.0M-$53.3M-$25.4M
Diluted shares57.4M62.3M63.9M62.4M60.9M13.2M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$47.3M$40.8M$32.5M$53.2M$232.8M$333.6M
Short-term investments$138.6M$195.7M$283.7M$368.0M$167.3M$98.3M
Total debt$0.00$0.00$0.00$0.00$0.00$0.00
Total assets$296.1M$366.6M$436.3M$487.9M$539.1M$442.3M
Total liabilities$36.8M$39.0M$39.4M$40.9M$36.2M$10.7M
Shareholders' equity$259.3M$327.6M$396.9M$447.0M$502.9M$431.6M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology